July 12, 2021
Chugai Pharmaceutical said on July 9 that it has entered into an option and license agreement with Shanghai-based Alebund Pharmaceuticals (Hong Kong) for its investigational drug, EOS789, for hyperphosphatemia. Under the deal, Alebund will carry out an early-stage efficacy study...read more